Physician profile
Jon Marie Cook
NPI 1487201794
$5,514.75
in general payments reported to CMS, 2019-2025
50 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $154 · 2023: $1,253 · 2024: $1,765 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,061 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,061.32 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $565.10 | 2023-2025 | Erleada, Talvey, Akeega |
| Novartis Pharmaceuticals Corporation | $503.18 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $455.75 | 2023-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $345.77 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Merck Sharp & Dohme LLC | $290.57 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Myriad Genetic Laboratories, INC. | $279.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $218.53 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $216.62 | 2023-2025 | |
| Daiichi Sankyo INC. | $203.08 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $180.41 | 2023-2025 | |
| Astellas Pharma US INC | $173.99 | 2024 | |
| Exelixis INC. | $152.98 | 2023-2025 | Cabometyx |
| Genentech USA, INC. | $152.05 | 2023-2025 | Polivy, Tecentriq, Phesgo |
| Celgene Corporation | $137.34 | 2024-2025 | Reblozyl |
| Deciphera Pharmaceuticals INC. | $99.67 | 2023-2025 | Qinlock, Romvimza, Tgct |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $99.67 | 2023-2025 | |
| Beigene USA, INC. | $98.28 | 2023-2025 | Brukinsa |
| Genmab U.S., INC. | $84.92 | 2023-2025 | Epkinly |
| Beone Medicines USA, INC. | $81.22 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $79.64 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Stemline Therapeutics INC. | $78.41 | 2024-2025 | Orserdu |
| Eisai INC. | $78.14 | 2023-2025 | |
| Abbvie INC. | $74.35 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.70 | 2025 | Fruzaqla |
| Pharmacosmos Therapeutics INC. | $63.89 | 2023-2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $55.86 | 2023-2025 | Fotivda |
| Seagen INC. | $53.05 | 2023 | Tukysa, Tivdak, Padcev |
| Karyopharm Therapeutics INC. | $49.33 | 2023-2024 | Xpovio |
| Glaxosmithkline, LLC. | $46.79 | 2024-2025 | Ojjaara, Blenrep |
| Servier Pharmaceuticals LLC | $46.65 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $41.87 | 2023-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $41.76 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $38.60 | 2023-2025 | |
| Immunocore Limited | $34.53 | 2025 | Kimmtrak |
| Sobi, INC | $31.19 | 2023-2024 | |
| Emd Serono, INC. | $28.60 | 2023-2024 | Bavencio |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Csl Behring | $25.14 | 2025 | Privigen |
| Pharmaessentia USA Corporation | $24.04 | 2024 | Besremi |
| Sun Pharmaceutical Industries INC. | $21.02 | 2025 | |
| Blueprint Medicines Corporation | $20.72 | 2023 | Ayvakit |
| Agios Pharmaceuticals, INC. | $20.26 | 2025 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $19.34 | 2023 | Imbruvica |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Vivimusta |
| Kite Pharma, INC. | $17.25 | 2025 | Yescarta |
| Taiho Oncology, INC. | $16.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2025 | |
| Puma Biotechnology, INC. | $15.25 | 2023 | Nerlynx |
| G1 Therapeutics, INC. | $14.13 | 2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $13.84 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Marie Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.